High insulinlike growth factor i is associated with cognitive decline in Huntington disease

Neurology

Volumn 75, Issue 1, 2010, Pages 57-63

  Saleh, N ^a,b,c   Moutereau, S ^a   Azulay, J P ^d   Verny, C ^e   Simonin, C ^f   Tranchant, C ^g   El Hawajri, N ^h   Bachoud Levi A C ^a,b,c,h   Maison, P ^a,b,c  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c INSERM U955   (France)

^d TIMONE HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h ECOLE NORMALE SUPÉRIEURE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; RATING SCALE;

EID: 77954650864     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e62076     Document Type: Article

References (40)

1. Brandt J. Cognitive Impairments in Huntington's Disease: Insights Into the Neuropsychology of Striatum. Amsterdam: Elsevier; 1991.
2. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006;24: 961-967.
3. Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007;18:223-251.
4. Petersen A, Hult S, Kirik D. Huntington's disease: new perspectives based on neuroendocrine changes in rodent models. Neurodegener Dis 2009;6:154-164.
5. Saleh N, Moutereau S, Durr A, et al. Neuroendocrine disturbances in Huntington's disease. PLoS One 2009;4: e4962.
6. Aleman A, Verhaar HJ, De Haan EH, et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab 1999;84:471-475.
7. Van Dam PS, Aleman A, de Vries WR, et al. Growth hormone, insulin-like growth factor I and cognitive function in adults. Growth Horm IGF Res 2000;10(suppl B):S69-S73.
8. Falleti MG, Maruff P, Burman P, Harris A. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 2006;31:681-691.
9. Connor B, Beilharz EJ, Williams C, et al. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Brain Res Mol Brain Res 1997;49:283-290.
10. Torres-Aleman I. Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opin Ther Targets 2007; 11:1535-1542.
11. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
12. Nagel BH, Palmbach M, Petersen D, Ranke MB. Magnetic resonance images of 91 children with different causes of short stature: pituitary size reflects growth hormone secretion. Eur J Pediatr 1997;156:758-763.
13. Juul A, Flyvbjerg A, Frystyk J, Muller J, Skakkebaek NE. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and-3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clin Endocrinol 1996;44:515-523.
14. Dik MG, Pluijm SM, Jonker C, Deeg DJ, Lomecky MZ, Lips P. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging 2003;24:573-581.
15. Arwert LI, Deijen JB, Drent ML. The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis. Growth Horm IGF Res 2005;15: 416-422.
16. Van Dam PS. Neurocognitive function in adults with growth hormone deficiency. Horm Res 2005;64(suppl 3): 109-114.
17. Sartorio A, Conti A, Molinari E, Riva G, Morabito F, Faglia G. Growth, growth hormone and cognitive functions. Horm Res 1996;45:23-29.
18. Arwert LI, Veltman DJ, Deijen JB, Lammertsma AA, Jonker C, Drent ML. Memory performance and the growth hormone/insulin-like growth factor axis in elderly: a positron emission tomography study. Neuroendocrinology 2005;81:31-40.
19. Van Dam PS, Aleman A. Insulinlike growth factor-I, cognition and brain aging. Eur J Pharmacol 2004;490:87-95.
20. Van Dam PS. Somatropin therapy and cognitive function in adults with growth hormone deficiency: a critical review. Treat Endocrinol 2006;5:159-170.
21. Sonntag WE, Ramsey M, Carter CS. Growth hormone and Insulinlike growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev 2005;4:195-212.
22. Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and Insulinlike growth factor-I related to neuropro-tection, regeneration, and functional plasticity in the adult brain. Scientific World Journal 2006;6:53-80.
23. Nyberg F. Growth hormone in the brain: characteristics of specific brain targets for the hormone and their functional significance. Front Neuroendocrinol 2000;21:330-348.
24. Busiguina S, Fernandez AM, Barrios V, et al. Neurodegen-eration is associated to changes in serum Insulinlike growth factors. Neurobiol Dis 2000;7:657-665.
25. Fernandez S, Fernandez AM, Lopez-Lopez C, Torres-Aleman I. Emerging roles of Insulinlike growth factor-I in the adult brain. Growth Horm IGF Res 2007;17:89-95.
26. Ferry RJ, Jr., Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of Insulinlike growth factor binding proteins. Horm Metab Res 1999;31:192-202. (Pubitemid 29169496)
27. Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, Sara VR. Insulinlike growth factors and Insulinlike growth factor binding proteins in cerebrospi-nal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 1993;5:165-176.
28. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Ras-kind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-168.
29. Trejo JL, Carro E, Garcia-Galloway E, Torres-Aleman I. Role of Insulinlike growth factor I signaling in neurode-generative diseases. J Mol Med 2004;82:156-162.
30. Torres-Aleman I, Barrios V, Berciano J. The peripheral Insulinlike growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998;50: 772-776.
31. Carro E, Torres-Aleman I. The role of insulin and insulinlike growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004;490:127-133.
32. Humbert S, Bryson EA, Cordelieres FP, et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002;2:831-837.
33. Freude S, Hettich MM, Schumann C, Stohr O, Koch L, Kohler C. Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J 2009;10:3315-3324.
34. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44:559-577.
35. Peschanski M, Cesaro P, Hantraye P. Rationale for intra-striatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995;68:273-285.
36. Douaud G, Gaura V, Ribeiro MJ, et al. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 2006;32:1562-1575.
37. Van den Berg G, Veldhuis JD, Frolich M, Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and pre-menopausal women. J Clin Endocrinol Metab 1996;81: 2460-2467.
38. Golden CJ. Stroop Color and Word Test. Chicago: Stoelt-ing; 1978.
39. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. New York: Psychological Corporation; 1981.
40. Cardebat D. Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 1990;90:207-217.